Margolin Sara, Werelius Barbro, Fornander Tommy, Lindblom Annika
Department of Oncology, Huddinge University Hospital, Södersjukhuset, S 118 83 Stockholm, Sweden.
Genet Test. 2004 Summer;8(2):127-32. doi: 10.1089/gte.2004.8.127.
The mutation frequency of BRCA1 and BRCA2 in women with breast cancer varies according to family history, age at diagnosis and ethnicity. The contribution of BRCA1 and BRCA2 mutations in breast cancer populations, unselected for age and family history, has been examined in several studies reporting mutation frequencies between 1% and 12% by screening methods, population sizes, and to what extent the gene/s were screened differed in the studies. We wanted to clarify the proportion of breast cancer attributable to mutations in BRCA1 in an unselected breast cancer population from the Stockholm region. All incident breast cancer patients treated surgically in a 19-month period were eligible for the study and 70% (489/696) participated. Exon 11 of BRCA1 was screened for mutations using the protein truncation test, and the mutation frequency was estimated from that. In previous studies on high-risk families from Stockholm, more than 70% of the mutations were detected in exon 11. Two mutations were found, both in patients with a family history or their own medical history of ovarian cancer, giving a mutation frequency in exon 11 of 0.4% and an estimated BRCA1 mutation frequency of <1%. Mutations in BRCA1 in unselected breast cancer cases in our region are rare and likely to be found only in high-risk families. Our BRCA1 prevalence is the lowest of all studies on unselected breast cancer patients, probably reflecting the comparatively low rates detected also in high-risk breast cancer families from the region.
患有乳腺癌的女性中,BRCA1和BRCA2的突变频率因家族史、诊断时的年龄和种族而异。在一些研究中,对未按年龄和家族史进行筛选的乳腺癌人群中BRCA1和BRCA2突变的贡献进行了研究,这些研究报告的突变频率在1%至12%之间,因筛选方法、人群规模以及研究中对基因筛选的程度不同而有所差异。我们想明确在斯德哥尔摩地区未经过筛选的乳腺癌人群中,由BRCA1突变导致的乳腺癌比例。在19个月期间接受手术治疗的所有新发乳腺癌患者均符合该研究的条件,70%(489/696)的患者参与了研究。使用蛋白质截短试验对BRCA1的第11外显子进行突变筛选,并据此估计突变频率。在之前对来自斯德哥尔摩的高危家族的研究中,超过70%的突变在第11外显子中被检测到。发现了两个突变,均在有卵巢癌家族史或自身病史的患者中,第11外显子的突变频率为0.4%,估计BRCA1突变频率<1%。在我们地区未经过筛选的乳腺癌病例中,BRCA1突变很少见,可能仅在高危家族中被发现。我们研究中BRCA1的患病率在所有关于未经过筛选的乳腺癌患者的研究中是最低的,这可能反映出在该地区高危乳腺癌家族中检测到的突变率也相对较低。